Acetazolamide (All indications)

Microcephaly / Small head circumference for gestational age

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S16074
R66707		 Christensen (Acetazolamide) (All indications) (Controls exposed to LTG), 2024 Microcephaly (z-score for head circumference ≤3rd percentile for gestational week, sex, and country (including newborns with congenital malformations)) during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 0.12 [0.01;1.97] C
excluded (control group) 		0/127   274/8,756 274 127
ref
S16046
R66601		 Christensen (Acetazolamide) (All indications) (Controls unexposed, general population), 2024 Microcephaly (z-score for head circumference ≤3rd percentile for gestational week, sex, and country (including newborns with congenital malformations)) during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) Adjustment: No 0.13 [0.01;2.05] C 0/127   134,023/4,467,848 134,023 127
ref
Total 1 studies 0.13 [0.01;2.05] 134,023 127
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Christensen (Acetazolamide) (All indications) (Controls unexposed, general population), 2024Christensen, 2024 1 0.13[0.01; 2.05]134,0231270%ROB confusion: criticalROB selection: lowROB classification: criticalROB missing: lowROB mesure: unclearROB reporting: moderate0.02.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Acetazolamide) (All indications) (Controls unexposed, general population;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.13[0.01; 2.05]134,023127 -NAChristensen (Acetazolamide) (All indications) (Controls unexposed, general population), 2024 1 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.13[0.01; 2.05]134,023127 -NAChristensen (Acetazolamide) (All indications) (Controls unexposed, general population), 2024 1 Tags Adjustment   - No  - No 0.13[0.01; 2.05]134,023127 -NAChristensen (Acetazolamide) (All indications) (Controls unexposed, general population), 2024 1 All studiesAll studies 0.13[0.01; 2.05]134,023127 -NAChristensen (Acetazolamide) (All indications) (Controls unexposed, general population), 2024 10.010.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 16074

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) Out of scale0.13[0.01; 2.05]134,023127 -NAChristensen (Acetazolamide) (All indications) (Controls unexposed, general population), 2024 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls Out of scale0.12[0.01; 1.97]274127 -NAChristensen (Acetazolamide) (All indications) (Controls exposed to LTG), 2024 10.510.01.0